Quarterly report · Q2
7090.TEDINET S100PJLS
Period2022-04-01 → 2022-09-30
Filed2022-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | −¥356m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥98m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | −¥365m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥151m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥92m | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥365m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥60m | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥266m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥72m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥32m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥266m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥32m | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥3.9bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥3.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥3.2bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.1bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥2.1bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥857m | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥1.1bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.1bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.4bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.4bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.4bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥182m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥80m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥8m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥552m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥475m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥190m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥766m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥154m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥209m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-188.99 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-85.09 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥51.64 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.12 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥11.61 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥50.55 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥22.53 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 21.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.7% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E33790-000Financial Services Segmentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥389m |
| jpcrp040300-q2r_E33790-000Financial Services Segmentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥389m |
| jpcrp040300-q2r_E33790-000Financial Services Segmentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥23m |
| jpcrp040300-q2r_E33790-000Osteopathic Solution Segmentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥848m |
| jpcrp040300-q2r_E33790-000Osteopathic Solution Segmentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥848m |
| jpcrp040300-q2r_E33790-000Osteopathic Solution Segmentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥333m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | −¥356m |
| jpcrp040300-q2r_E33790-000Financial Services Segmentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥490m |
| jpcrp040300-q2r_E33790-000Financial Services Segmentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥490m |
| jpcrp040300-q2r_E33790-000Financial Services Segmentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥29m |
| jpcrp040300-q2r_E33790-000Osteopathic Solution Segmentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E33790-000Osteopathic Solution Segmentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E33790-000Osteopathic Solution Segmentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥70m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥1.7bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥1.7bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥98m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 512
| Item | Context | Value | Unit |
|---|---|---|---|
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 31087000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 1910653000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 1361973000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 1502530000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 1393060000 | JPY |
| Directors compensations sga | Prior1YTDDuration | 91920000 | JPY |
| Directors compensations sga | CurrentYTDDuration | 113830000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 253045000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 297754000 | JPY |
| Share based compensation expenses sga | Prior1YTDDuration | 11223000 | JPY |
| Share based compensation expenses sga | CurrentYTDDuration | 12242000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 18432000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 23780000 | JPY |
| Traveling and transportation expenses sga | Prior1YTDDuration | 35224000 | JPY |
| Traveling and transportation expenses sga | CurrentYTDDuration | 44106000 | JPY |
| Commission fee sga | Prior1YTDDuration | 81345000 | JPY |
| Commission fee sga | CurrentYTDDuration | 121922000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | -278000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | 631000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E33790-000OsteopathicSolutionSegmentsReportableSegmentsMember | 1169989000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E33790-000FinancialServicesSegmentsReportableSegmentsMember | 489922000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 1659911000 | JPY |
| Revenues from external customers | Prior1YTDDuration | 1659911000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E33790-000OsteopathicSolutionSegmentsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E33790-000FinancialServicesSegmentsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E33790-000OsteopathicSolutionSegmentsReportableSegmentsMember | 1169989000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E33790-000FinancialServicesSegmentsReportableSegmentsMember | 489922000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 1659911000 | JPY |
| Net sales | Prior1YTDDuration | 1659911000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E33790-000OsteopathicSolutionSegmentsReportableSegmentsMember | 69532000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E33790-000FinancialServicesSegmentsReportableSegmentsMember | 28623000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 98156000 | JPY |
| Operating income | Prior1YTDDuration | 98156000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E33790-000OsteopathicSolutionSegmentsReportableSegmentsMember | 847517000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E33790-000FinancialServicesSegmentsReportableSegmentsMember | 389151000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 1236668000 | JPY |
| Revenues from external customers | CurrentYTDDuration | 1236668000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E33790-000OsteopathicSolutionSegmentsReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E33790-000FinancialServicesSegmentsReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E33790-000OsteopathicSolutionSegmentsReportableSegmentsMember | 847517000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E33790-000FinancialServicesSegmentsReportableSegmentsMember | 389151000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 1236668000 | JPY |
| Net sales | CurrentYTDDuration | 1236668000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E33790-000OsteopathicSolutionSegmentsReportableSegmentsMember | -333282000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E33790-000FinancialServicesSegmentsReportableSegmentsMember | -23114000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | -356397000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |